康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09966 康宁杰瑞制药-B

交易中 11-19 15:19:09

4.510

+0.010

+0.22%

最高4.740	最低4.320	成交量425.40万
今开4.600	昨收4.500	日振幅9.33%
总市值43.47亿	流通市值43.47亿	总股本9.64亿
成交额1,908万	换手率0.44%	流通股本9.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":4.51,"timestamp":1732000690877,"preClose":4.5,"halted":0,"volume":4254000,"delay":0,"floatShares":963901807,"shares":963901807,"eps":-0.2357471,"marketStatus":"交易中","marketStatusCode":2,"change":0.01,"latestTime":"11-19 15:19:09","open":4.6,"high":4.74,"low":4.32,"amount":19082346,"amplitude":0.093333,"askPrice":4.52,"askSize":7000,"bidPrice":4.51,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.24670543174672355,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732003800000},"adr":0,"listingDate":1576080000000,"adjPreClose":4.5,"openAndCloseTimeList":[[1731979800000,1731988800000],[1731992400000,1732003200000]],"volumeRatio":0.58951,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"2484560149","title":"康宁杰瑞制药-B盘中异动 早盘快速拉升5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484560149","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484560149?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:04","pubTimestamp":1731981847,"startTime":"0","endTime":"0","summary":"2024年11月19日早盘10时04分，康宁杰瑞制药-B股票出现波动，股价急速上涨5.11%。截至发稿，该股报4.730港元/股，成交量74.8004万股，换手率0.08%，振幅4.22%。康宁杰瑞制药-B股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，云顶新耀-B、百奥赛图-B、康希诺生物涨幅较大，振幅较大的相关个股有晶泰科技、百奥赛图-B、科济药业-B，振幅分别为9.17%、9.00%、8.27%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家投资控股公司,主要从事生物制药业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119100407a24463a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119100407a24463a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2483958773","title":"康宁杰瑞制药-B盘中异动 早盘急速跳水5.07%报4.680港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483958773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483958773?lang=zh_cn&edition=full","pubTime":"2024-11-15 11:15","pubTimestamp":1731640538,"startTime":"0","endTime":"0","summary":"2024年11月15日早盘11时15分，康宁杰瑞制药-B股票出现异动，股价大幅下跌5.07%。截至发稿，该股报4.680港元/股，成交量388.8万股，换手率0.40%，振幅8.92%。资金方面，该股资金流入551.797万港元，流出985.26万港元。康宁杰瑞制药-B股票所在的生物技术行业中，整体涨幅为0.36%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家投资控股公司,主要从事生物制药业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115111538abc2f95a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115111538abc2f95a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2483539630","title":"康宁杰瑞制药-B(09966)下跌5.07%，报4.68元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483539630","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483539630?lang=zh_cn&edition=full","pubTime":"2024-11-15 11:15","pubTimestamp":1731640537,"startTime":"0","endTime":"0","summary":"11月15日，康宁杰瑞制药-B(09966)盘中下跌5.07%，截至11:15，报4.68元/股，成交1875.58万元。康宁杰瑞生物制药是一家专门致力于抗肿瘤领域生物创新药的开发、生产和商业化的公司，拥有具有自主知识产权的生物大分子药物发现、研发、生产技术平台。公司位于苏州工业园区的研发与产业化基地按照NMPA、FDA和EMA的GMP标准建设，总设计规模超过4万升，第一期生产线已经获得生产许可证并通过了欧盟QP和美国客户的审计。截至2024年中报，康宁杰瑞制药-B营业总收入1.74亿元、净利润-4489.6万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/15111545326336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2483427788","title":"康宁杰瑞制药-B11月14日主力资金流入86万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483427788","media":"市场透视","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483427788?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:15","pubTimestamp":1731572152,"startTime":"0","endTime":"0","summary":"11月14日, 康宁杰瑞制药-B股价涨9.56%，报收4.93元，成交金额8756万元，换手率1.86%，振幅13.33%，量比2.06。康宁杰瑞制药-B今日主力资金净流入86万元，连续5日净流入，上一交易日主力净流入22万元，今日环比增加290.91%。近一年数据显示，该股主力连续5日净流入后，次日上涨概率为66.67%，平均涨幅为6.99%。该股近5个交易日上涨27.91%，主力资金累计净流入469万元；近20日主力资金累计净流入412万元，其中净流入天数为9日。该股主力净额占比0.02%，港股市场排名121/2644。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161614abc04ef0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114161614abc04ef0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2483891626","title":"康宁杰瑞制药-B现涨逾12% HER2双抗ADC皮下注射复方制剂首次公布临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2483891626","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483891626?lang=zh_cn&edition=full","pubTime":"2024-11-14 11:37","pubTimestamp":1731555426,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B早盘上涨12.67%，现报5.07港元，成交额4735.2万港元。11月13日，康宁杰瑞生物制药宣布，HER2双特异性抗体偶联药物（ADC）与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的一项临床试验（研究编号：JSKN033-102）符合《优化创新药临床试验审评审批试点工作方案》相关要求，获得上海市药品监督管理局（经药品审评中心（CDE）同意）纳入试点项目，将按要求向CDE提交临床试验申请，预计通过快速通道进行审评审批，以加速启动该项针对晚期恶性肿瘤的Ⅰ/Ⅱ期临床研究。\n\n\r\n            责任编辑：栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14113745279354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK4231","BK1574","BK4080","09966","ADC"],"gpt_icon":0},{"id":"2483089935","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超12% HER2双抗ADC皮下注射复方制剂首次公布临床结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2483089935","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483089935?lang=zh_cn&edition=full","pubTime":"2024-11-14 11:11","pubTimestamp":1731553884,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超12%，截至发稿，涨12.67%，报5.07港元，成交额4735.2万港元。此前，康宁杰瑞公布HER2双特异性抗体偶联药物与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的首次人体临床研究结果。该研究入选了2024年第39届癌症免疫治疗学会年会最新突破性摘要，于会议期间以壁报形式首次公布。本研究进一步证明了ADC联合免疫治疗的潜力，并支持对JSKN033的持续探索。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","09966","BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"2483895473","title":"康宁杰瑞制药-B(09966)上涨10.0%，报4.95元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483895473","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483895473?lang=zh_cn&edition=full","pubTime":"2024-11-14 10:46","pubTimestamp":1731552412,"startTime":"0","endTime":"0","summary":"11月14日，康宁杰瑞制药-B(09966)盘中上涨10.0%，截至10:46，报4.95元/股，成交2953.2万元。康宁杰瑞生物制药是一家专门致力于抗肿瘤领域生物创新药的开发、生产和商业化的公司，拥有具有自主知识产权的生物大分子药物发现、研发、生产技术平台。公司位于苏州工业园区的研发与产业化基地按照NMPA、FDA和EMA的GMP标准建设，总设计规模超过4万升，第一期生产线已经获得生产许可证并通过了欧盟QP和美国客户的审计。截至2024年中报，康宁杰瑞制药-B营业总收入1.74亿元、净利润-4489.6万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14104645278262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2483024962","title":"康宁杰瑞制药-B11月13日获主力加仓22万元 环比增加1000.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483024962","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483024962?lang=zh_cn&edition=full","pubTime":"2024-11-13 16:16","pubTimestamp":1731485767,"startTime":"0","endTime":"0","summary":"11月13日, 康宁杰瑞制药-B股价涨0.45%，报收4.50元，成交金额2262万元，换手率0.54%，振幅5.80%，量比0.63。康宁杰瑞制药-B今日主力资金净流入22万元，连续4日净流入，上一交易日主力净流入2万元，今日环比增加1000.00%。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为66.67%，平均涨幅为16.15%。该股近5个交易日上涨16.71%，主力资金累计净流入352万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入425万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161638a233242d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113161638a233242d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2483160250","title":"康宁杰瑞制药-B(09966)下跌5.13%，报4.25元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483160250","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483160250?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:41","pubTimestamp":1731465668,"startTime":"0","endTime":"0","summary":"11月13日，康宁杰瑞制药-B(09966)盘中下跌5.13%，截至10:41，报4.25元/股，成交913.74万元。康宁杰瑞生物制药是一家专门致力于抗肿瘤领域生物创新药的开发、生产和商业化的公司，拥有具有自主知识产权的生物大分子药物发现、研发、生产技术平台。公司位于苏州工业园区的研发与产业化基地按照NMPA、FDA和EMA的GMP标准建设，总设计规模超过4万升，第一期生产线已经获得生产许可证并通过了欧盟QP和美国客户的审计。截至2024年中报，康宁杰瑞制药-B营业总收入1.74亿元、净利润-4489.6万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13104145232527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09966","BK1161","BK1574"],"gpt_icon":0},{"id":"2483111015","title":"康宁杰瑞制药-B盘中异动 早盘快速下挫5.13%报4.250港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483111015","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483111015?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:41","pubTimestamp":1731465666,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时41分，康宁杰瑞制药-B股票出现波动，股价急速下跌5.13%。截至发稿，该股报4.250港元/股，成交量210.5万股，换手率0.22%，振幅5.13%。资金方面，该股资金流入281.057万港元，流出525.052万港元。康宁杰瑞制药-B股票所在的生物技术行业中，整体跌幅为2.34%。康宁杰瑞制药-B公司简介：康宁杰瑞生物制药是一家投资控股公司,主要从事生物制药业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113104106971a62ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113104106971a62ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2483001517","title":"康宁杰瑞HER2双抗ADC皮下注射复方制剂JSKN033一项Ⅰ/Ⅱ期临床研究获纳入优化创新药临床试验审评审批试点项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2483001517","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483001517?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:59","pubTimestamp":1731463140,"startTime":"0","endTime":"0","summary":"此次获纳入优化创新药临床试验审评审批试点项目，是对康宁杰瑞差异化创新管线产品的认可，将加速JSKN033在中国的临床开发进程，早日为肿瘤患者带来更安全、有效且依从性更高的治疗选择。关于JSKN033 JSKN033是康宁杰瑞自主研发的全球首个抗体偶联药物和免疫检查点抑制剂的高浓度皮下注射复方制剂, 由JSKN003和恩沃利单抗组成。目前JSKN033正在澳大利亚开展用于治疗HER2表达晚期或转移性实体瘤的Ⅰ/Ⅱ期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4555353_ZH55353_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4512","BK1574","LU0348723411.USD","BK4231","IE00BFMHRM44.USD","09966","BK4148","ADC","BK4585","BK4080","BK4588","BK1161","GLW"],"gpt_icon":0},{"id":"2482733724","title":"康宁杰瑞制药-B11月12日主力资金流入2万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2482733724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482733724?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:15","pubTimestamp":1731399309,"startTime":"0","endTime":"0","summary":"11月12日, 康宁杰瑞制药-B股价涨0.67%，报收4.48元，成交金额3248万元，换手率0.76%，振幅6.52%，量比1.00。康宁杰瑞制药-B今日主力资金净流入2万元，连续3日净流入，上一交易日主力净流入243万元，今日环比减少99.18%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为45.45%，平均涨幅为3.86%。该股近5个交易日上涨15.76%，主力资金累计净流入319万元；近20日主力资金累计净流入344万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161516abb93190&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161516abb93190&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2482205012","title":"入选LBA！康宁杰瑞HER2双抗ADC皮下注射复方制剂JSKN033最新突破性临床研究结果亮相2024年SITC年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2482205012","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482205012?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:04","pubTimestamp":1731301440,"startTime":"0","endTime":"0","summary":"苏州2024年11月11日 /美通社/ -- 康宁杰瑞生物制药宣布，HER2双特异性抗体偶联药物与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的首次人体临床研究结果入选2024年第39届癌症免疫治疗学会年会最新突破性摘要，于会议期间以壁报形式首次公布。本研究进一步证明了ADC联合免疫治疗的潜力，并支持对JSKN033的持续探索。关于JSKN033 JSKN033是康宁杰瑞自主研发的全球首个抗体偶联药物和免疫检查点抑制剂的高浓度皮下注射复方制剂, 由JSKN003和恩沃利单抗组成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4552740_ZH52740_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4148","LU0348723411.USD","BK4231","SITC","BK4080","BK4585","BK1161","09966","BK4512","BK4588","GLW","ADC","BK1574","IE00BFMHRM44.USD"],"gpt_icon":0},{"id":"2482521091","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超5% JSKN033研究成果入选SITC年会最新突破性摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2482521091","media":"智通财经","labels":["Product Release","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482521091?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:44","pubTimestamp":1731289497,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超5%，截至发稿，涨5.08%，报4.34港元，成交额1135.22万港元。消息面上，康宁杰瑞制药-B发布公告，集团自主研发的用于治疗HER2 表达晚期或转移性实体瘤的JSKN033的I/II期临床试验的最新研究成果入选2024年SITC年会最新突破性摘要，且于年会期间以壁报形式首次公布，公司网站亦相应公布了此研究成果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK4080","SITC","BK4231","09966"],"gpt_icon":0},{"id":"2482621780","title":"康宁杰瑞制药-B盘中异动 股价大涨5.33%报4.350港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482621780","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482621780?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:30","pubTimestamp":1731288609,"startTime":"0","endTime":"0","summary":"2024年11月11日早盘09时30分，康宁杰瑞制药-B股票出现异动，股价急速拉升5.33%。截至发稿，该股报4.350港元/股，成交量47.8万股，换手率0.05%，振幅1.94%。资金方面，该股资金流入26.973万港元，流出45.807万港元。康宁杰瑞制药-B股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，康宁杰瑞制药-B、和誉-B、乐普生物-B涨幅较大，振幅较大的相关个股有药明生物、科济药业-B、和誉-B，振幅分别为3.27%、3.17%、2.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111109300998e419ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111109300998e419ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2482263792","title":"康宁杰瑞制药(09966.HK)JSKN033研究成果入选SITC年会最新突破性摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2482263792","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482263792?lang=zh_cn&edition=full","pubTime":"2024-11-10 21:03","pubTimestamp":1731243780,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药－Ｂ(09966.HK) 公布，集团自主研发的用于治疗HER2表达晚期或转移性实体瘤的JSKN033的I/II期临床试验最新研究成果入选2024年SITC年会最新突破性摘要，且于年会期间以壁报形式首次公布。结论是JSKN033安全性良好，在多线治疗后疾病进展的实体瘤患者中初步显示出令人鼓舞的抗肿瘤活性。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-08 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191009132909636_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1395444/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2482066252","title":"康宁杰瑞制药JSKN033临床试验初步结果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2482066252","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482066252?lang=zh_cn&edition=full","pubTime":"2024-11-10 19:03","pubTimestamp":1731236607,"startTime":"0","endTime":"0","summary":"财中社11月10日电康宁杰瑞制药-B（09966）发布自愿公告，介绍其自主研发的JSKN033在2024年SITC年会上的最新研究成果。该研究为I/II期临床试验，主要评估JSKN033在晚期HER2表达实质瘤或HER2突变非小细胞肺癌患者中的安全性、耐受性和初步有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411103234754097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","09966","BK1161","BK1574","03347","BK1583","BK1576"],"gpt_icon":0},{"id":"2482259712","title":"康宁杰瑞制药-B(09966)：于2024年SITC年会呈列的JSKN033的I/II期临床试验的最新研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2482259712","media":"智通财经","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482259712?lang=zh_cn&edition=full","pubTime":"2024-11-10 18:11","pubTimestamp":1731233464,"startTime":"0","endTime":"0","summary":"有关研究结果概述如下：JSKN033-101是一项开放、多中心及首次人体的I/II期临床试验，旨在评估 JSKN033在晚期HER2表达实体瘤或HER2突变非小细胞肺癌患者中的安全性、耐受性和初步有效性。JSKN033在4.5mg/kg剂量下即对患者表现出抗肿瘤活性。结论：JSKN033安全性良好，在多线治疗后疾病进展的实体瘤患者中初步显示出令人鼓舞的抗肿瘤活性。本研究进一步证明了免疫治疗联合ADC治疗的潜力，并支持对JSKN033的进一步探索。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4080","BK4231","BK1574","BK1576","SITC","03347","BK1141","BK1161","09966"],"gpt_icon":0},{"id":"2481191641","title":"医药股早盘部分走高 科济药业-B涨超33%康宁杰瑞制药-B涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481191641","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481191641?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:59","pubTimestamp":1731038378,"startTime":"0","endTime":"0","summary":"医药股早盘部分走高 ，科济药业-B（02171）上涨32.34%，报8.88港元；康宁杰瑞制药-B（09966）上涨8.01%，报4.18港元；云顶新耀-B（01952）上涨5.23%，报34.20港元；乐普生物-B（02157）上涨4.59%，报3.19港元；宜明昂科-B（01541）上涨3.28%，报7.54港元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-08/doc-incvinss3992567.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-08/doc-incvinss3992567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1585","BK1161","BK1515","BK1574","02171","BK1587","09966","09939"],"gpt_icon":0},{"id":"2481416046","title":"港股异动 | 部分医药股走高 医保谈判支持创新药 机构指板块仍有进一步修复空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2481416046","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481416046?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:48","pubTimestamp":1731034083,"startTime":"0","endTime":"0","summary":"消息面上，据国家医保局此前介绍，2024年国家医保药品目录调整现场谈判已顺利结束，“扩容”后的新版医保药品目录预计于11月底对外发布，2025年1月1日起正式实施。西南证券表示，创新药国谈和三季报落地。创新药国谈方向投资机会值得期待。交银国际表示，近期医药板块在大幅震荡后小幅回升，考虑到板块估值仍处于历史底部、叠加后续宏观利好政策出台+流动性改善，该行认为仍有进一步修复空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","02171","01952","BK1583","BK1161","06978","02157","BK1585","159992","09966","BK1587","09939","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":0.0112},{"period":"1month","weight":0.125},{"period":"3month","weight":0.751},{"period":"6month","weight":-0.0816},{"period":"1year","weight":-0.2823},{"period":"ytd","weight":-0.3223}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家投资控股公司，主要从事生物制药业务。公司专注于研发、生产和商业化创新肿瘤免疫生物大分子靶向药物的全产业链企业。公司拥有生物创新药开发技术平台，包括蛋白质工程平台、多功能抗体开发平台和抗体筛选平台。该公司在海内外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.131218},{"month":2,"riseRate":0.6,"avgChangeRate":0.11167},{"month":3,"riseRate":0,"avgChangeRate":-0.116679},{"month":4,"riseRate":1,"avgChangeRate":0.117691},{"month":5,"riseRate":0.4,"avgChangeRate":-0.096701},{"month":6,"riseRate":0.4,"avgChangeRate":0.026634},{"month":7,"riseRate":0.2,"avgChangeRate":-0.0532},{"month":8,"riseRate":0.4,"avgChangeRate":0.041129},{"month":9,"riseRate":0.2,"avgChangeRate":0.094086},{"month":10,"riseRate":0.4,"avgChangeRate":-0.004359},{"month":11,"riseRate":0.6,"avgChangeRate":0.101409},{"month":12,"riseRate":0.75,"avgChangeRate":0.015223}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}